1IBHub — The targeted B2B partnering platform for pharmaceutical in-licensing, out-licensing and cross-border portfolio growth.

1IBHub

News & Industry Deal Insights

Structured breakdowns of pharmaceutical business development, licensing and M&A transactions — written for portfolio and BD decision makers.

Strategic Biopharma Transactions: Bispecific Antibodies, Targeted Radioligands, and Genomic RNA Platforms

Recent biopharma dealmaking highlights continuous capital allocation toward clinically validated bispecific antibodies, targeted radioligand therapeutics, and novel non-coding RNA (lncRNA) drug discovery engines. Multi-billion dollar transaction structures reflect Big Pharma's willingness to commit substantial upfront capital to secure ex-China global commercialization rights, particularly in oncology and auto-immunity.

  • M&A
  • Licensing
  • Bispecifics
  • Radiopharmaceuticals
  • lncRNA
Read Full Article

Strategic Biopharma Transactions: Bankruptcy Asset Auctions, GI-Restricted Kinase Mergers, and Oral Immunology Capital

Recent biopharma dealmaking reflects a distinct shift toward capital efficiency, valuation discipline, and specialized modality consolidation. Transactions were anchored by Section 363 bankruptcy asset auctions, corporate reverse mergers paired with PIPE financing, oral immunology alternatives, and synthetic royalty monetization.

  • M&A
  • Licensing
  • Bankruptcy Auctions
  • Immunology
  • ADCs
Read Full Article

Stay Connected on LinkedIn

Follow 1IBHub on LinkedIn for latest job offerings, news, and deal analysis in pharmaceutical business development.

Follow 1IBHub on LinkedIn